Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
INSERM currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, SZPERKA, MICHAEL EDWARD, who is also the busiest examiner for the portfolio. The prosecution is situated within 1 distinct art unit, which limits the examination of this specific biotechnology filing to a single group. This focus is common in specialized pharmaceutical patent applications.
SZPERKA, MICHAEL EDWARD is responsible for 1 busiest examiner pending action, which represents the totality of the pending workload for the company. The presence of 1 distinct art unit and 1 distinct examiner indicates that the 1 pending office action is being reviewed by a single individual. Practitioners can expect a single point of contact for the 1 pending office action currently active. This data reflects the current engagement with the patent office, as all metrics point to 1 examiner and 1 art unit. This concentration simplifies the management of the company's biotechnology intellectual property.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
| BERA, HENA RAKESHKUMAR | 1 | 100.0% | +0.0% |
| DARPOLOR, JOSEPHINE KEBBEH | 1 | 62.1% | +39.3% |
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18846458 | USE OF BAZEDOXIFENE FOR INCREASING MUSCLE SURVIVAL | SHIAO, REI TSANG | — |
| 18573728 | COMPOSITIONS AND METHODS FOR PERMEABILIZING THE BLOOD BRAIN BARRIER | HOPKINS, SAMANTHA LAKE | — |
| 18571892 | METHODS FOR DIAGNOSING A CANCER- OR ANTIBIOTICS-INDUCED DYSBIOSIS AND THEIR USE FOR IMPROVING CANCER TREATMENT BY IMMUNOTHERAPY | BERA, HENA RAKESHKUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17791549 | MULTISPECIFIC ANTIBODIES THAT BIND BOTH MAIT AND TUMOR CELLS | DARPOLOR, JOSEPHINE KEBBEH | 78d overdue |
| 18573728 | COMPOSITIONS AND METHODS FOR PERMEABILIZING THE BLOOD BRAIN BARRIER | HOPKINS, SAMANTHA LAKE | — |
| 17474334 | METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1641 | 1 |
| 1798 | 1 |
| 1642 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18846458 | USE OF BAZEDOXIFENE FOR INCREASING MUSCLE SURVIVAL | SHIAO, REI TSANG | 1691 | §103§112 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18573728 | COMPOSITIONS AND METHODS FOR PERMEABILIZING THE BLOOD BRAIN BARRIER | HOPKINS, SAMANTHA LAKE | 1641 | §103§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18571892 | METHODS FOR DIAGNOSING A CANCER- OR ANTIBIOTICS-INDUCED DYSBIOSIS AND THEIR USE FOR IMPROVING CANCER TREATMENT BY IMMUNOTHERAPY | BERA, HENA RAKESHKUMAR | 1798 | §101§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 17791549 | MULTISPECIFIC ANTIBODIES THAT BIND BOTH MAIT AND TUMOR CELLS | DARPOLOR, JOSEPHINE KEBBEH | 1642 | §103 | Non-Final OA | 78d overdue | Pending | Jul 08, 2022 |
| 17474334 | METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS | SALMON, KATHERINE D | 1682 | §103Other | Non-Final OA | — | Pending | Sep 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInserm (institut National de La Sante Et de La Recherche Medicale) has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Rei Tsang Shiao has the most, with 1 of Inserm (institut National de La Sante Et de La Recherche Medicale)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
